James Pipkin

Dr. Pipkin joined Ligand in 2011, following Ligand's acquisition of CyDex Pharmaceuticals. He joined CyDex in 2001. Dr. Pipkin's responsibilities include development of new applications, intellectual property and products utilizing Captisol both internally and assisting clients, whether the application involves new molecular entities, an Orphan designated drug or reformulations of existing drugs for lifecycle management via the 505(b)(2) regulatory pathway. Prior to joining Ligand, he was Executive Director for CMC Services and Director of Formulation Development at Oread Laboratories from 1995 to 2001. From 1986 through 1995, he was a Research Fellow with Merck Research Laboratories in the INTERx Research Division and West Point PR&D facilities; his area of research was in the design and evaluation of controlled-release devices for ophthalmic and oral delivery to enhance therapeutic efficacy and lower systemic burden. He was at The Squibb Institute for Medical Research from 1980 through 1985, where he directed the pre-formulation activities for new chemical entities. He has contributed to numerous presentations, publications and patents and holds MS and PhD degrees from The University of Kansas in pharmaceutical chemistry, and a BA in mathematics and chemistry from Kansas University.